Biological agents in management of osteoporosis.

Biological agents in management of osteoporosis.

Item
http://www.wikidata.org/entity/Q38247465
Hypoxic regulation of osteoclast differentiation and bone resorption activityIdentification of Osteoporosis-Associated Protein Biomarkers from Ovariectomized Rat UrineSclerostin inhibition: a novel therapeutic approach in the treatment of osteoporosis.Hemin activation of innate cellular response blocks human immunodeficiency virus type-1-induced osteoclastogenesis.Hypoxia-Induced Fibroblast Growth Factor 11 Stimulates Osteoclast-Mediated Resorption of Bone.GSK-3β Inhibition Suppresses Instability-induced Osteolysis by a Dual Action on Osteoblast and Osteoclast Differentiation.Hypoxia-inducible factor 1-alpha does not regulate osteoclastogenesis but enhances bone resorption activity via prolyl-4-hydroxylase 2.BMP-2 Enhances Lgr4 Gene Expression in Osteoblastic Cells.Biologic adjuvants and bone: current use in orthopedic surgery.Multiple Roles of Angiopoietin-Like 4 in Osteolytic DiseaseThe relationship between postmenopausal women's sclerostin levels and their bone density, age, body mass index, hormonal status, and smoking and consumption of coffee and dairy products.Self-assembling bisphosphonates into nanofibers to enhance their inhibitory capacity on bone resorption.
P2860

Biological agents in management of osteoporosis.

Item
http://www.wikidata.org/entity/Q38247465
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Biological agents in management of osteoporosis.
@en
type
label
Biological agents in management of osteoporosis.
@en
prefLabel
Biological agents in management of osteoporosis.
@en
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P433
P478
P577
P6179
P698
P921
P356
P1433
P1476
Biological agents in management of osteoporosis.
@en
P2093
P2860
P2888
P304
P31
P356
P433
P478
P577
P6179
P698
P921